Novavax, Inc. (NVAX)
Novavax, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Gaithersburg, MD, US. The stock last traded at $7.47, down 3.24% on the session, giving a market capitalisation of $1.23B. On trailing twelve-month figures it carries a trailing P/E of -16.24, a net margin of -18.6%. Its beta of 2.72 implies it has historically moved more than the broad market.
Novavax, Inc. is a biotechnology firm dedicated to discovering, developing, and commercializing vaccines aimed at preventing serious infectious diseases and addressing critical health needs. The company's diverse pipeline includes NVX-CoV2373, a coronavirus vaccine candidate currently undergoing two Phase III trials, one Phase IIb, and one Phase I/II trial. Also featured is NanoFlu, a nanoparticle-based seasonal quadrivalent influenza vaccine in Phase 3 clinical trials. Furthermore, Novavax is advancing ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine, which is in Phase II clinical trials for adults aged 60 and older, and in Phase I for pediatric use. The company holds a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of its COVID-19 vaccine candidate, NVX-CoV2373. Established in 1987, Novavax, Inc. is headquartered in Gaithersburg, Maryland.
Novavax, Inc. is most often compared with the following Healthcare names: